, Dec. 18, 2014
/PRNewswire-USNewswire/ -- Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report, "Twenty-Five Years of Progress Against Hepatitis C: Setbacks and Stepping Stones
that examines the scientific challenges and setbacks researchers have
faced on the path to developing new medicines with the potential to
transform treatment for hepatitis C patients and how these so-called
"failures" are an integral part of the drug discovery process.
new report found between 1998 and 2014, 77 investigational medicines
failed in clinical trials, laying the groundwork for 12 approved
medicines over the same period.
learnings from these setbacks inform the continuous innovation in
treatment leading to new advances in treating the hepatitis C virus. The
evolution of treatment from interferon-based therapy to direct-acting
antiviral agents has helped transform hepatitis C from a chronic and
often fatal illness to an infection that with new and forthcoming
treatments may one day be considered a rare disease.
the trajectory of hepatitis C is changing thanks to America's
biopharmaceutical companies, substantial unmet medical need for patients
remains, which is why the industry continues to research further
treatment advances for patients. According to the report, there are 75
new hepatitis C medicines either in clinical trials or awaiting review
by the U.S. Food and Drug Administration (FDA).
and forthcoming hepatitis C treatments represent a remarkable advance
against a very serious disease," said PhRMA President and CEO John J. Castellani.
"These treatments are often curing more than 90 percent of patients –
transforming lives and helping to avert billions of dollars in
unnecessary hospitalizations and other costly medical services.
Forthcoming treatments are projected to provide even greater cure rates
and shorter duration of treatment, vastly improving patients' health and
quality of life."
C is the leading cause of liver transplants and the primary driver of
increases in liver cancer. The costs of treating hepatitis C can be
daunting with average health care costs per patient battling liver
cancer estimated at $112,000 per year and the cost of a liver transplant ranging as high as $500,000
per patient. These costs underscore the importance of new therapies in
treating and potentially curing the disease for both patients and the
health care system.
Pharmaceutical Research and Manufacturers of America (PhRMA) represents
the country's leading innovative biopharmaceutical research and
biotechnology companies, which are devoted to discovering and developing
medicines that enable patients to live longer, healthier, and more
productive lives. Since 2000, PhRMA member companies have invested more
than $550 billion in the search for new treatments and cures, including an estimated $51.1 billion in 2013 alone.
SOURCE Pharmaceutical Research and Manufacturers of America
Labels: clinical development, history of HCV, pharmaceutical industry, Research and Discoveries